TITLE

THERATECHNOLOGIES GETS US $12 MILLION FOR MACROFLUX

PUB. DATE
February 2005
SOURCE
Worldwide Biotech;Feb2005, Vol. 17 Issue 2, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents information on the grant received by Theratechnologies from Alza Corp. for the co-development projects of Macroflux transdermal drug delivery technology, in February 2005. Key priorities for Theratechnologies; Components of the co-development project; Expectations on the partnership.
ACCESSION #
15887763

 

Related Articles

  • New analgesia device is needle-free. LoBuono, Charlotte // Drug Topics;7/24/2006, Vol. 150 Issue 14, pHSE10 

    The article reports that the U.S. Food and Drug Administration has approved the fentanyl iontophoretic transdermal system from Alza Corp. The device is the first needle-free, patient-activated transdermal analgesic system for short-term management of acute postoperative pain in pain in patients...

  • Press Release.  // Internet Journal of Dermatology;2002, Vol. 1 Issue 1, p7 

    This article offers information, education and training to users of central venous catheters and to improve patient safety by raising awareness for potential complications. Topics include, a 15 minutes overview about central venous catheters (CVC), an in-depth review with 10 multimedia learning...

  • The need for rules and regulations. Helmus, Michael N. // Nature Nanotechnology;Jun2007, Vol. 2 Issue 6, p333 

    The article deals with the need for implementing rules and regulations that govern new drugs and medical devices before nanomedicine can be commercialized in the U.S. According to the author, nanoparticles can improve the biocompatibility of medical instruments, whereas drugs and nanostructured...

  • Equidyne to Launch Needle-Free Insulin Injector. Webb, Marion // San Diego Business Journal;05/15/2000, Vol. 21 Issue 20, p38 

    Reports on San Diego, California-based Equidyne Corp.'s launching of INJEX, a needle-free insulin injector. Breakthrough alternative to other needle-free systems; Description of how to use the needle-free insulin injector kit; Retail price. INSET: Numbers of Diabetes Patients Rising in U.S..

  • Ralstonia Associated with Vapotherm Oxygen Delivery Device -- United States, 2005. Arias, K.; Bamford, O.; Lain, D.; Niland, B.; Storey, B.; Thibodeau, K.; Campagna, L.; Borowitz, D.; Serlen, R.; Johnson, C.; Dash, G.; Coffin, S.; St. John, K.; Hedgman, A.; Atkins, J.; Quattlebaum, B.; Hudak, P.; Wahrmund, C.; Snow, B.; Stein, B. // MMWR: Morbidity & Mortality Weekly Report;10/21/2005, Vol. 54 Issue 41, p1052 

    Reports on the identification of the Vapotherm 2000i oxygen delivery device as an associated risk factor for recovery of Ralstonia from blood and respiratory tract samples in Pennsylvania in August 2005. Functions of the Vapotherm device; Description of Ralstonia; Development of...

  • Drug delivery showing strength in wake of drug efficacy efforts.  // Chemical Market Reporter;09/08/97, Vol. 252 Issue 10, p13 

    Reports on the status of the market for drug delivery systems in the United States. Analysis on the growth of the industry; Leading categories for drug delivery systems; Current worldwide sales of drug delivery systems.

  • Life after Syntex. Zaffaroni, Alejandro // Chemical Heritage;Summer2005, Vol. 23 Issue 2, p9 

    Recalls a work experience and life after working for Syntex. Background on the foundation of Alza Corp. in 1968; Acquisition of Alza by Johnson & Johnson in 1981; Information on the possibility of cigarette as a drug-delivery device.

  • Thinking Outside The Eyedropper. Abelson, Mark B.; Torkildsen, Gail; Shapiro, Aron // Review of Ophthalmology;Sep2005, Vol. 12 Issue 9, p78 

    Discusses various efforts to improve ophthalmic eyedrop drug delivery. Technical challenge of creating a smaller drop; Failure of past attempts at delivery of medications in alternative forms; Extraocular drug delivery products under development which avoid the pitfalls of standard eyedrop...

  • Usability of devices for self-injection: results of a formative study on a new disposable pen injector. Lange, Jakob; Richard, Philipp; Bradley, Nick // Medical Devices: Evidence & Research;2014, Vol. 7, p195 

    This article presents a late-stage formative usability study of a pen-injector platform device. Such devices are used for the subcutaneous delivery of biopharmaceuticals, primarily for self-administration by the patient. The study was conducted with a broad user population, defined to represent...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics